Effective long‐term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy
- 23 November 2010
- journal article
- clinical trial
- Published by Wiley in International Journal of Dermatology
- Vol. 49 (12), 1445-1449
- https://doi.org/10.1111/j.1365-4632.2010.04638.x
Abstract
Hidradenitis suppurativa is a chronic suppurative condition featuring inflammatory nodules, fistulas and scars. It occurs predominantly in the axillae and groin. The disease is poorly responsive to any treatment and is connected with significant morbidity. Systemic therapy, including oral antibiotics, retinoids and antiandrogens, usually has only limited effect. Surgical treatment of affected areas is necessary in advanced stages. Several reports support the beneficial effect of tumor necrosis factor-α (TNF-α) antagonists for the treatment of severe hidradenitis suppurativa. By contrast with data on infliximab and etanercept, data describing the potential positive influence of adalimumab on disease outcome are limited and refer to only small cohorts of patients. Eight patients with severe, recalcitrant hidradenitis were treated for 1 year with adalimumab in a standard regimen and were subsequently followed for 1 year. All patients improved within 4-6 weeks and laboratory parameters of C-reactive protein (CRP) and leukocyte count reduced significantly during treatment. Three patients demonstrated long-lasting improvement and five showed recurrences several months after discontinuation of the therapy. The average recurrence-free interval was 9.5 months. Adalimumab is suitable for the long-term treatment of hidradenitis suppurativa and presents a further conservative treatment approach.Keywords
This publication has 22 references indexed in Scilit:
- Treatment of severe recalcitrant hidradenitis suppurativa with adalimumabJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2009
- Behandlung einer therapierefraktären Hidradenitis suppurativa mit AdalimumabJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2009
- Hidradenitis suppurativa: are tumour necrosis factor-α blockers the ultimate alternative?British Journal of Dermatology, 2008
- An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativaBritish Journal of Dermatology, 2007
- Long-term infliximab for severe hidradenitis suppurativaBritish Journal of Dermatology, 2006
- Dioxin‐induced chloracne – reconstructing the cellular and molecular mechanisms of a classic environmental diseaseExperimental Dermatology, 2006
- Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumabJournal of the American Academy of Dermatology, 2006
- Etanercept: effective in the management of hidradenitis suppurativaBritish Journal of Dermatology, 2006
- Surgical treatment of hidradenitis suppurativa: A 10-year experienceSurgery, 2005
- Acne inversa (alias hidradenitis suppurativa)Journal of the European Academy of Dermatology and Venereology, 2001